In spontaneously hypertensive rats receiving MLN-4760, zofenopril calcium improved erythrocyte osmotic resistance. The deformability response was limited, and RBC DCF fluorescence did not significantly decrease. These are animal-treatment findings with subsequent blood assays. [2]
In obese Zucker diabetic fatty rats, four weeks of oral zofenopril calcium lowered systolic blood pressure and improved isolated-aorta relaxation and contraction relative to obese controls. The authors reported no significant improvement in glucose tolerance under their test conditions. [3]
Acute H2S and nitrite responses in healthy mice
Animal study · Male C57BL/6J mice, 10–14 weeks old [1]
A single oral dose increased H2S at 8 h, with no significant change at 1 or 24 h. Nitrite increased at 8 h. H2S-producing enzyme protein levels were unchanged; eNOS Ser1177 phosphorylation showed a nonsignificant trend. The ramipril comparator did not significantly alter these gasotransmitter endpoints. These measurements do not establish direct ACE potency or prove that the parent molecule directly releases H2S.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Single dose
- Treatment course
- 1, 8 or 24 h endpoints
- Vehicle
- Carboxymethylcellulose 0.2% m/v
- Zofenopril calcium
- Model: Healthy male C57BL/6J mice
Methods and source locations
Compound reported in the paper: Zofenopril calcium; Compound label in the paper: Calcium salt, Menarini Ricerche S.p.A.
Applies to the reported calcium-form material and animal conditions; no validation of this SKU or any Adooq lot.
Methods: Animals, Treatment, H2S and NO measurements, Western Blot, Statistical Analysis; Results associated with Figures 1–3
Plasma and myocardial H2S at 8 h; time-course limits: Gas chromatography/sulfur chemiluminescence; Figure 1: plasma n=8 zofenopril at 8 h, n=7 vehicle; myocardium n=13 per group. — Results: Zofenopril Increases H2S Bioavailability In Vivo; Figure 1A–B; H2S method
Plasma and myocardial nitrite at 8 h: HPLC; Figure 2: plasma n=12 zofenopril and n=13 vehicle; myocardium n=8 per group. — Results: Zofenopril Activates eNOS and Increases NO Bioavailability; Figure 2A–B; NO-metabolite method
H2S enzyme proteins and eNOS phosphorylation/expression at 8 h: Western blots normalized to GAPDH or total eNOS as labeled; n=8/group for H2S enzyme proteins, n=6/group for eNOS endpoints; mean±SEM. — Figures 1C–F and 2C–F; corresponding Results; Western Blot method
H2S and nitrite after ramipril comparator: Ramipril 3 mg/kg orally; Figures 3A–D; gas chromatography and HPLC. Separate vehicle groups; not a direct head-to-head superiority test. — Treatment: Murine study; Results: Ramipril, a Dicarboxylate ACEI, Does Not Affect H2S and NO Bioavailability; Figure 3A–D
Zofenopril calcium · Methods: Animals and Treatment; Figures 1–3
Erythrocyte responses after zofenopril with or without ACE2 inhibition
Animal study · Spontaneously hypertensive rats entering at 16 weeks; C n=12, CZ n=7, M n=12, MZ n=12 assigned [2]
Zofenopril improved osmotic resistance in MLN-4760-treated rats. Deformability showed an interaction but only a nonsignificant tendency to improve in untreated SHRs; no reduction in the RBC DCF fluorescence endpoint was detected. Ex vivo RBC readouts follow animal dosing and are represented as one animal study.
- CZ: zofenopril without MLN
- Model: Spontaneously hypertensive rats
- Route: Oral, mixed with food
- Frequency: Daily
- Treatment course: Days 5–14
- MZ: zofenopril plus MLN-4760
- Model: Spontaneously hypertensive rats under pharmacological ACE2 inhibition
- Route: Zofenopril oral in food; MLN subcutaneous pump
- Frequency: Daily zofenopril; continuous MLN
- Treatment course: Zofenopril days 5–14; MLN 14 days
Methods and source locations
Compound reported in the paper: Zofenopril calcium; Compound label in the paper: Zofenopril calcium, AdooQ Bioscience LLC
Applies to the reported calcium-form material and animal conditions; no validation of this SKU or any Adooq lot.
Methods 2.1, 2.7, 2.9, 2.11–2.12; Results 3.8, 3.10; Figures 4 and 6
RBC osmotic resistance: Whole-blood hypotonic NaCl hemolysis assay; IC50 here denotes the NaCl concentration producing 50% hemolysis, not drug potency. Results shown as mean±SD; no exact ordinate value inferred. — Methods 2.11–2.12; Results 3.8; Figure 4b and caption
RBC deformability: Filtration through 5 μm pores; fraction of cells passing filter. Figure displays mean±SD; endpoint sample sizes can differ after outlier removal. — Methods 2.7, 2.12; Results 3.8; Figure 4a
RBC DCF-related fluorescence: DCF fluorescence microscopy assay on isolated RBCs; mean±SD. This assay does not establish universal absence of oxidative stress. — Methods 2.9, 2.12; Results 3.10; Figure 6a
CZ: zofenopril without MLN · Methods 2.1; Results 3.8, 3.10; Figures 4a and 6a
MZ: zofenopril plus MLN-4760 · Methods 2.1; Results 3.8, 3.10; Figures 4b and 6a
Four-week vascular response in obese diabetic rats
Animal study · Male Zucker diabetic fatty rats: lean fa/+ (L), obese fa/fa (O), treated obese (OZ); n=8 per group [3]
Four weeks of zofenopril calcium reduced systolic blood pressure and improved aortic acetylcholine relaxation and noradrenaline contraction relative to obese controls. The reported glucose-tolerance test showed no significant treatment improvement; no general metabolic correction is inferred.
Conditions shared by the study groups
- Route
- Oral, mixed with food
- Frequency
- Daily
- Treatment course
- 4 weeks
- OZ: zofenopril-treated obese rats
- Model: Male obese fa/fa ZDF rats
Methods and source locations
Compound reported in the paper: Zofenopril calcium; Compound label in the paper: Zofenopril calcium, AdooQ Bioscience
Applies to the reported calcium-form material and animal conditions; no validation of this SKU or any Adooq lot.
Materials and Methods: Animals/design, Blood pressure measurements, Vascular reactivity studies, Statistical analysis, Drugs; Figure 1a–d and associated Results
Terminal systolic blood pressure: Tail-cuff plethysmography; mean of at least 5 stable readings per reported value; n=8/group, mean±SEM; one-way ANOVA with Bonferroni tests. No exact bar heights extracted. — Blood pressure measurements; Results associated with Figure 1a; Figure 1 caption
Isolated thoracic-aorta relaxation and contraction after animal dosing: Organ-bath tension recording; acetylcholine applied to noradrenaline-precontracted rings; relaxation expressed relative to precontraction. n=8/group, mean±SEM; two-way ANOVA/Bonferroni. No exact curve values inferred. — Vascular reactivity studies; Results associated with Figure 1c–d; Figure 1 caption
Post-treatment glucose tolerance: Intraperitoneal glucose-tolerance test; n=8/group, mean±SEM. The printed loading dose is unusual and is not adopted or corrected; interpretation is confined to the authors' reported comparison. — Intraperitoneal glucose tolerance test; Results associated with Figure 1b; Figure 1 caption
OZ: zofenopril-treated obese rats · Animals/design and Drugs methods; Figure 1a–d